Moderna Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Moderna Inc 's ROA in the second quarter of 2026?
Moderna Inc had a negative return on assets (ROA) of -26.61%, due to the net loss of $-3 billion, during the twelve months ending in the second quarter of 2026.

However, within the Healthcare sector 401 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3577, from total ROA ranking in the first quarter of 2026 at 4127.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-8.73 %	-9.57 %	-9.57 %	-23.21 %	-23.41 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-3,151	-3,194	-2,822	-3,116	-2,903
Return On Assets (TTM)	-26.61 %	-26.39 %	-22.74 %	-24.44 %	-21.24 %
MRNA's Total Ranking	# 3577	# 4127	# 3638	# 3607	# 3699
Total Assets (TTM) in million	10,961	11,488	12,788	12,135	12,010
Seq. Total Assets Change	-4.59 %	-10.17 %	5.38 %	1.04 %	-5.46 %
Seq. Net Income Change	-	-	-	-	-

MRNA's 5 Years Annual ROA >> Back to MRNA Management Effectiveness >> Compare MRNA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 42
Sector	# 402
Overall	# 3550

Return On Assets Statistics
High	Average	Low
72.07 %	-49.72 %	-452.81 %
(Sep 30 2015)		(Dec 31 2019)

Financial Statements
Moderna Inc 's Assets	$ 10,961 million	MRNA's Balance sheet
Moderna Inc 's Income	$ -782 million	Quarterly MRNA's Income Statement
MRNA's Income by Division		See MRNA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	3.76 %	-23.25 %	-28.74 %	4.87 %	236.53 %
Total Assets in million	14,674	14,142	18,426	25,858	24,657
Y / Y Net Income Change	-	-	-	-31.47 %	-
Net Income in million	-2,822	-3,561	-4,714	8,362	12,202
Annual Return On Assets	-19.23 %	-25.18 %	-25.58 %	32.34 %	49.49 %

MRNA's 5 Years Annual ROA >> Back to MRNA Management Effectiveness >> Compare MRNA ROA to its Competitors

More Return On Assets Ratios
MRNA's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
MRNA's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for MRNA's Competitors
Subscribers only: Roa for Moderna Inc 's Suppliers
Subscribers only: Return On Assets for MRNA's Customers

You may also want to know
MRNA's Roi	MRNA's Inventory Turnover Ratio	MRNA's Growth Rates	MRNA's Dividend Comparisons
	MRNA's Profitability Ratios	MRNA's Asset Turnover Ratio	MRNA's Dividend Growth
MRNA's Roe	MRNA's Valuation Ratios	MRNA's Financial Strength Ratios	MRNA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:37:49+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.